Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer

Eur J Cancer. 2006 Dec;42(18):3219-27. doi: 10.1016/j.ejca.2006.05.033. Epub 2006 Aug 28.

Abstract

Aim: E-cadherin plays a role in carcinogenesis. For two genetic polymorphisms in the gene (CDH1) promoter, a reduced transcription has been reported: a C/A single nucleotide polymorphism (SNP) and a G/GA SNP at -160 bp and -347 bp, respectively, upstream of the transcriptional start site. We studied the association between both polymorphisms and the risk of bladder cancer.

Methods: One hundred and ninety-seven patients with bladder cancer and 344 population controls were genotyped and haplotyped for both SNPs.

Results: A borderline significantly increased risk for bladder cancer was found for A allele carriers (OR 1.36; 95% CI: 0.96-1.94). We did not find any association between the -347 G/GA SNP and bladder cancer. Haplotype analyses did not yield much stronger associations with bladder cancer than the -160 C/A genotype analyses.

Conclusion: This study supports earlier suggestions that the -160 C/A SNP in the CDH1 promoter is a risk factor for bladder cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cadherins / genetics*
  • Gene Frequency
  • Genotype
  • Haplotypes / genetics
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic / genetics*
  • Risk Factors
  • Urinary Bladder Neoplasms / genetics*

Substances

  • Cadherins